Salvia

Salvia

Helmut Jeggle established Salvia in 2014 as a first-generation single family office. The firm began with traditional angel investments and evolved into an entrepreneurial venture capital investor focused on deep tech and science-based startups. Wealth originated from Jeggle’s position as an early BioNTech investor and current supervisory board chair. Salvia targets angel through growth stages in direct co-investments and SPVs. Asset classes include venture equity, private equity, and distressed situations. Portfolio holdings comprise Bambusa Therapeutics, IQM, ONE DATA, Wingcopter, and Group14 Technologies. Confirmed geographies cover Europe and North America. The office also records prior exits including Aldevron to Danaher in 2021 and BioNTech’s 2019 IPO. The team consists of four named professionals led by Jeggle as Founder & Managing Partner. No additional offices appear in public records. In May 2026 Bambusa Therapeutics completed patient enrollment in its Phase-1b/2a atopic dermatitis trial. In February 2026 IQM announced a merger filing with Real Asset Acquisition Corp. that would create the first listed European quantum company. Salvia maintains an integrated operating-company relationship with its portfolio. The structure allows direct application of Jeggle’s company-building experience and global networks to active board and advisory roles rather than passive capital allocation.